Study reveals diverse risk factors for healthy aging in Latin America

Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

Af­ter a sec­ond re­view, the FDA ap­proved Zevra Ther­a­peu­tics’ treat­ment for Nie­mann-Pick dis­ease type C, a pro­gres­sive rare ge­net­ic dis­ease caused by the ac­cu­mu­la­tion of